FDA-cleared profile

Transpara (2.1.0)

ScreenPoint Medical B.V. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.

Clinical role
Concurrent reading aid for screening mammography and DBT interpretation.
Images and patients
Mammography/DBT · Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
Key limitation
Keep in mind: The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K241831 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for concurrent reading of screening FFDM and DBT from systems compatible with Transpara 2.1.0.

Limits to check

  • Region and examination scores support physician review. They must not be the sole basis for management, and do not establish a separate density-module license.

Questions for the vendor and your team

  1. Which version, acquisition-system combinations and licensed outputs are included in the offer?
  2. How will the team test displayed regions and exam scores alongside full image interpretation and record exceptions?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image interpretation · source-reviewed 2026-11-09

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis Input: DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.
  • Who uses it?Intended users: Physicians qualified to interpret screening mammography and digital breast tomosynthesis.
  • What does the software produce?Output: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.
  • What is its most important limitation?Key limitation: The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.

Clinical takeaway. Clinical role: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.

Evidence takeaway. Evidence from the reviewed source record: K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K241831 · agent source review 2026-11-12 · exact submission

Existing study anchor: K241831 FDA evidence package for Transpara (2.1.0). Tested version label: Transpara 2.1.0.

What was tested?

Transpara 2.1.0 standalone detection on FFDM and DBT, plus separate temporal-comparison and subgroup analyses.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

On which cases and versions?

The main test set had 10,207 exams including 1,350 biopsy-proven cancers, from multiple centers in seven European countries and the US. Prior-exam analyses and manufacturer combinations are separate subgroups.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

What changed?

The summary reports non-inferior and superior standalone performance versus Transpara 1.7.2 and improved performance with temporal comparison versus without. Sensitivity depends on operating point and modality; false-positive rates are regions per image in non-cancer exams.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

What does this not establish?

Standalone operating-point sensitivity is not an aided-reader outcome or a recall-rate guarantee. Subgroup and overlapping lesion classifications cannot be added. The existing separate literature study is not newly admitted or broadened by this card.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

Study design, population and missing context
evidence Role
Standalone external-to-development test dataset and separate temporal-comparison analyses, not a reader workflow trial.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

design
Standalone algorithm evaluation against reference classification and the Transpara 1.7.2 predicate; test data not used for algorithm development.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

setting
Multiple clinical centers in seven European countries and the United States; test sources separate from development.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
10,207 exams: 5,730 FFDM and 4,477 DBT; 1,350 biopsy-proven cancer exams, 270 benign and 8,587 normal.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

reference Standard
Biopsy-proven cancer; most normal exams had at least one year normal follow-up.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

comparator
Transpara 2.1.0 versus Transpara 1.7.2 for standalone processing; temporal analyses also compare processing with versus without priors.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM: Hologic, GE, Philips, Siemens and Fujifilm; DBT: Hologic, Siemens, GE and Fujifilm. Temporal-comparison combinations have a separate, narrower compatibility table.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sample Composition
Cancer: 1,350/10,207 exams; benign: 270/10,207; normal: 8,587/10,207. Lesion-type and histology categories are not summed across overlapping classifications.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sponsor Involvement
ScreenPoint submitted the regulatory standalone package. A held-out dataset does not by itself establish investigator independence.

regulatory summary · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K241831 · agent source review 2026-11-09 · Transpara 2.1.0

Authorized population

Women undergoing screening mammography or digital breast tomosynthesis.

Label age limits

Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Modality and protocol

Screening FFDM and DBT exams from compatible FFDM and DBT systems.

Acquisition constraints

Requires compatible FFDM and DBT systems; system compatibility is specific to the exact record.

Exclusions and human review

Adjunct tool, not a replacement for a physician's own mammogram review. Patient management decisions must not be based solely on Transpara.

Purpose
Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Concurrent reading aid for screening mammography and DBT interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Healthcare facilities performing screening mammography and digital breast tomosynthesis.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Physicians qualified to interpret screening mammography and digital breast tomosynthesis.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
70%; 80%; 97%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
70%; 80%; 97%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

FFDM sensitivity at 70% specificity

97.4 percent

  • EndpointSensitivity at the FDA-reported operating point
  • Population5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
  • Tested versionTranspara 2.1.0

DBT sensitivity at 70% specificity

96.9 percent

  • EndpointSensitivity at the FDA-reported operating point
  • Population4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
  • Tested versionTranspara 2.1.0

FFDM exam-based AUC

0.96 AUC

  • EndpointExam-based discrimination
  • Population5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
  • Tested versionTranspara 2.1.0

DBT exam-based AUC

0.955 AUC

  • EndpointExam-based discrimination
  • Population4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
  • Tested versionTranspara 2.1.0

K241831 FDA evidence package for Transpara (2.1.0)

  • DesignFDA 510(k) standalone performance evaluation of FFDM and DBT exams from a multicenter test set representative of screening and diagnostic breast imaging practice.
  • Population10,207 examinations including 1,350 biopsy-proven cancers; FFDM and DBT cohorts from seven European countries and the United States.
  • Scopeexact submission
  • Tested versionTranspara 2.1.0
  • Samplen=10207
  • IndependenceSponsor or vendor study

K241831

FDA-reported results for the exact Transpara 2.1.0 submission.

Performance across different versions of an artificial intelligence model for screen-reading of mammograms

  • DesignRetrospective multicenter registry cohort comparing Transpara versions 1.7 and 2.1.
  • Population117,709 screening examinations including 737 screen-detected and 200 interval cancers from two breast centers.
  • Scopeexact product version
  • Tested versionTranspara 2.1
  • Samplen=117709
  • Sites2
  • IndependenceIndependence not established

PMID:41528472

The PubMed record explicitly identifies Transpara version 2.1. The article reports the major-minor release label; no broader Transpara-family claim is promoted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K241831 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

Sectra IDS7

Not reviewed for this pairing

  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed.
  • Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build.
  • Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.
  • Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

Existing route context (at most two)

Broader supplier context
  • Not reviewed for this pairing
  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed.
  • Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build.
  • Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.
  • Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Sectra Amplifier Marketplace: Transpara Breast AI · Sectra IDS7 28.2 public webinar program · Sectra Workstation/Core 28.1 conformance, March 2026

  1. Acquisition/source

    Source context, not route validation: DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  2. Routing

    Source context, not route validation: The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  3. AI processing

    Source context, not route validation: The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  4. Returned objects

    Source context, not route validation: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  5. Viewer/worklist/report

    Unresolved route: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.
  • Exact FDA submission
  • Checked 2026-09-04
Security
ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Use by physicians qualified to interpret screening mammography and digital breast tomosynthesis. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K241831.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K241831.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K241831.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241831
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-11-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

Transpara reading aid

Open the documented family

A partial mapping of two reviewed FDA submissions. Evidence, compatible inputs, licensing and availability remain specific to each record.

The K241831 summary names Transpara 1.7.2 K221347 and describes the two versions. Transpara Density is a different module and is not mapped here.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. Related FDA recordTranspara 1.7.2 (K221347)

    Transpara 1.7.2

    FDA decision: 2022-08-03 · record reviewed 2026-11-09
  2. This FDA recordTranspara (2.1.0) (K241831)

    Transpara 2.1.0

    Latest mapped FDA decisionFDA decision: 2024-11-25 · record reviewed 2026-11-09

Documented names and scope

  • Transpara 1.7.2 · K221347. Name for this exact FDA record, not an alias for every commercial configuration. Name source
  • Transpara 2.1.0 · K241831. Name for this exact FDA record, not an alias for every commercial configuration. Name source

Transpara reading aid

Concurrent screening mammography and DBT reading aid. Applies to K221347, K241831. This describes the mapped function only; feature parity and a shared license are not established.

Availability evidence, separate from FDA decisions

  • not established

    Current availability of an exact FDA-submission configuration is not established. Ask the supplier for the offered release and licensed modules.

  • historical statement · Transpara 2.1 · United States announcement; exact local supply not established · statement dated 2024-12-02

    Historical vendor announcement of Transpara 2.1 and options. Does not establish an offered exact FDA configuration today.

    Availability source
Latest FDA decision among these records
K241831 · 2024-11-25. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
18Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads

Promoted PMID 41528472 because its record explicitly tests Transpara version 2.1. The other 17 PubMed records and all 6 trial records were quarantined because they are unrelated, unversioned, or test Transpara 1.6, 1.7, 1.7.1, 1.7.3, or 2.0.0 rather than the exact 2.1 release. The current discovery snapshot contains 18 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

13 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K241831: Transpara (2.1.0)

    U.S. Food and Drug Administration - Published 2024-11-25 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Transpara (2.1.0) model card (K241831)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Performance across different versions of an artificial intelligence model for screen-reading of mammograms

    European Radiology via PubMed - Accessed 2026-09-04

    Scope: evidence, exact_product_version, clinical_performance

  9. ScreenPoint Medical Security Reporting

    ScreenPoint Medical - Accessed 2026-10-25

    Scope: security

  10. Sectra Amplifier Marketplace: Transpara Breast AI

    Sectra - Accessed 2026-11-06

    Scope: product_family_implementation

  11. FDA K221347: Transpara 1.7.2

    U.S. Food and Drug Administration - Published 2022-08-03 - Accessed 2026-11-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, product_family

  12. FDA 510(k) decision material K241831: Transpara (2.1.0)

    U.S. Food and Drug Administration - Published 2024-11-25 - Accessed 2026-11-09

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence, product_family

  13. Transpara 2.1 announcement

    ScreenPoint Medical - Published 2024-12-02 - Accessed 2026-11-09

    Scope: product_family

Research history

  1. K241831 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K254131

BAC

DeepHealth, Inc.

Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2026-05-21
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history